The expression of four genes as a prognostic classifier for stage I lung adenocarcinoma in 12 independent cohorts

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 12, 2014, Pages 2884-2894

  Okayama, Hirokazu ^a   Schetter, Aaron J ^a   Ishigame, Teruhide ^a   Robles, Ana I ^a   Kohno, Takashi ^b   Yokota, Jun ^c   Takenoshita, Seiichi ^d   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c Institute of Predictive and Personalized Medicine of Cancer   (Spain)

^d FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; DLC1 PROTEIN; EXPORTIN 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADENOCARCINOMA; COHORT ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; PROGNOSIS;

ADENOCARCINOMA; BIOMARKERS, TUMOR; COHORT STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PROGNOSIS;

EID: 84919346292     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0182     Document Type: Article

References (45)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Pignon JP, Tribodet H, Scagliotti G.V., Douillard JY, Shepherd FA, Stephens RJ, et al Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26: 3552-9.
3. NCCN Clinical Practice Guidelines in Oncology. Available from: http://www.nccn.org.
4. Howington JA, Blum MG, Chang A.C., Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e278S-313S.
5. Arriagada R, Auperin A, Burdett S., Higgins JP, Johnson DH, Le Chevalier T, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010; 375: 1267-77.
6. Butts CA, Ding K, Seymour L., Twumasi-Ankrah P, Graham B, Gandara D., et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010; 28: 29-34.
7. Strauss GM, Herndon JE II, Maddaus MA, Johnstone DW, Johnson EA, Harpole D.H., et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26: 5043-51.
8. Nitadori J, Bograd AJ, Kadota K, Sima C.S., Rizk NP, Morales EA, et al. Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2 cm or smaller. J Natl Cancer Inst 2013; 105: 1212-20.
9. Goldstraw P, Crowley J, Chansky K., Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2: 706-14.
10. Church TR, Black WC, Aberle D.R., Berg CD, Clingan KL, Duan F, et al Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med 2013; 368: 1980-91.
11. Zhu CQ, Ding K, Strumpf D., Weir BA, Meyerson M, Pennell N, et al Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 2010; 28: 4417-24.
12. Shedden K, Taylor JM, Enkemann S.A., Tsao MS, Yeatman TJ, Gerald WL, et al Gene expression-based survival prediction in lung adeno-carcinoma: a multi-site, blinded validation study. Nat Med 2008; 14:822-7.
13. Chen HY, Yu SL, Chen C.H., Chang GC, Chen CY, Yuan A, et al A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007; 356: 11-20.
14. Beer DG, Kardia SL, Huang C.C., Giordano TJ, Levin AM, Misek DE, et al Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002; 8: 816-24.
15. Lau SK, Boutros PC, Pintilie M, Blackhall F.H., Zhu CQ, Strumpf D, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 2007; 25: 5562-9.
16. Tomida S, Takeuchi T, Shimada Y., Arima C, Matsuo K, Mitsudomi T., et al. Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol 2009; 27: 2793-9.
17. Lee ES, Son DS, Kim S.H., Lee J., Jo J, Han J, et al Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res 2008; 14: 7397-404.
18. Boutros PC, Lau SK, Pintilie M, Liu N., Shepherd FA, Der SD, et al. Prognostic gene signatures for non-small-cell lung cancer. Proc Natl Acad Sci U S A 2009; 106: 2824-8.
19. Bianchi F, Nuciforo P, Vecchi M., Bernard L, Tizzoni L, Marchetti A., et al. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest 2007; 117: 3436-44.
20. Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, et al. A practical molecular assay to predict survival in resected non-squa-mous, non-small-cell lung cancer: development and international validation studies. Lancet 2012; 379: 823-32.
21. Raz DJ, Ray MR, Kim J.Y., He B., Taron M, Skrzypski M, et al A multigene assay is prognostic of survival in patients with early-stage lung ade-nocarcinoma. Clin Cancer Res 2008; 14: 5565-70.
22. Sun Z, Wigle DA, Yang P. Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol 2008; 26: 877-83.
23. Roepman P, Jassem J, Smit E.F., Muley T., Niklinski J, van de Velde T, et al. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res 2009; 15: 284-90.
24. Tang H, Xiao G, Behrens C., Schiller J, Allen J, Chow C.W., et al. A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. Clin Cancer Res 2013; 19: 1577-86.
25. Chen DT, Hsu YL, Fulp W.J., Coppola D., Haura EB, Yeatman TJ, et al. Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. J Natl Cancer Inst 2011; 103:1859-70.
26. Guo NL, Wan YW, Tosun K, Lin H., Msiska Z, Flynn DC, et al Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res 2008; 14: 8213-20.
27. Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 2010; 102:464-74.
28. Wistuba II, Behrens C, Lombardi F., Wagner S, Fujimoto J, Raso M.G., et al. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin Cancer Res 2013; 19: 6261-71.
29. Akagi I, Okayama H, Schetter A.J., Robles AI, Kohno T, Bowman ED, et al Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma. Cancer Res 2013; 73: 3821-32.
30. Botling J, Edlund K, Lohr M., Hellwig B, Holmberg L, Lambe M., et al. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res 2013; 19: 194-204.
31. Rousseaux S, Debernardi A, Jacquiau B., Vitte AL, Vesin A, Nagy-Mignotte H, et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med 2013; 5:186ra66.
32. Matsuyama Y, Suzuki M, Arima C., Huang QM, Tomida S, Takeuchi T, et al Proteasomal non-catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomas. Mol Carcinog 2011; 50: 301-9.
33. Wilkerson MD, Yin X, Walter V., Zhao N, Cabanski CR, Hayward M.C., et al. Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. PLoS ONE 2012; 7:e36530.
34. Bild AH, Yao G, Chang J.T., Wang Q., Potti A, Chasse D, et al Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353-7.
35. Bhattacharjee A, Richards WG, Staunton J, Li C., Monti S, Vasa P, et al Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001; 98: 13790-5.
36. Okayama H, Kohno T, Ishii Y., Shimada Y, Shiraishi K, Iwakawa R., et al. Identification of Genes Up-regulated in ALK-positive and EGFR/KRAS/ALK-negative Lung Adenocarcinomas. Cancer Res 2012; 72: 100-11.
37. Wilkerson MD, Yin X, Hoadley K.A., Liu Y., Hayward MC, Cabanski CR, et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clin Cancer Res 2010; 16: 4864-75.
38. Raponi M, Zhang Y, Yu J., Chen G, Lee G, Taylor J.M., et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 2006; 66: 7466-72.
39. Larsen JE, Pavey SJ, Passmore L.H., Bowman R., Clarke BE, Hayward NK, et al. Expression profiling defines a recurrence signature in lung squamous cell carcinoma. Carcinogenesis 2007; 28: 760-6.
40. Higgins JP, Thompson SG, Deeks J.J., Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
41. Herbst RS, Heymach JV, Lippman SM Lung cancer. N Engl J Med 2008; 359: 1367-80.
42. Goncalves R, Bose R. Using multigene tests to select treatment for early-stage breast cancer. J Natl Compr Canc Netw 2013; 11: 174-82.
43. Reis-Filho J.S., Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011; 378: 1812-23.
44. Yang M, Shen H, Qiu C., Ni Y, Wang L, Dong W., et al. High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur J Cancer 2012; 49: 604-15.
45. Wang Y, Li J, Tong L., Zhang J, Zhai A, Xu K., et al. The prognostic value of miR-21 and miR-155 in non-small-cell lung cancer: a meta-analysis. Jpn J Clin Oncol 2013; 43: 813-20.